You searched for "disease"
Surgical risk prediction
Patients presenting for urological surgery range from the young and fit to the elderly with multiple, and often significant, coexistent diseases. This latter cohort can present a significant challenge in the perioperative period, sometimes irrespective of the type of surgery....Movember launches world’s largest cancer real world evidence network
Movember has launched the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year. The leading...Urology around the world: An overview of healthcare in Germany
Germany boasts a highly developed and comprehensive healthcare system, renowned for its quality and accessibility. The urology landscape in the country mirrors this overall excellence, characterised by a well-structured network of specialists, advanced technology, and a strong emphasis on patient-centered...The role of PET-CT imaging in prostate cancer
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...
Does maternal exposure during pregnancy to higher ambient temperature increase the risk of hypospadias?
The search for the causes of hypospadias continues at a pace. These authors from Turkey extrapolated other findings about the higher incidence of congenital anomalies in babies during summer months’ gestation to studying the risks of high ambient temperature during...
RN or PN for small RCCs – the debate continues
This is a retrospective study to evaluate kidney function and overall survival (OS) in patients who underwent partial nephrectomy (PN) and radical nephrectomy (RN) for RCCs <4cm. They looked at 2110 patients who underwent RN/PN for T1a renal cell carcinomas...
First and second-line treatments in metastatic renal cell carcinoma
Over the past two decades, the treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly, leading to a quadrupling of patient survival rates. Modern systemic treatments include combinations of anti-PD-1 antibodies with either anti-CTLA-4 antibodies or antiangiogenic tyrosine...
